The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > News > Physiogenex to present its NASH hamster model at the Keystone Symposium on Obesity and NAFLD

News detail

Return to all news & events

01/18/2018 Physiogenex to present its NASH hamster model at the Keystone Symposium on Obesity and NAFLD

Physiogenex will present at the Keystone Symposia on Obesity and NAFLD in Keystone, CO, USA, January 22th-25th, 2018.

Dr. François Briand, Director of Research and Business Development, will be presenting a poster (#1011) on Monday, January the 22nd, about the effects of elafibranor (GFT505) in the Diet-Induced NASH (DIN) hamster model.

Looking forward to meet you there!

About Physiogenex

Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications. We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We focus on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.

Please visit our website for more information